The Wistar Institute's Albert R. Taxin Brain Tumor Research Center Receives National Recognition

April 22, 1998

Philadelphia -- The Wistar Institute's Albert R. Taxin Brain Tumor Research Center was nationally distinguished by the announcement of a $350,000 challenge grant award from The Kresge Foundation, one of the nation's 15 largest independent, private foundations.

"The Kresge Foundation is very selective and their grant making process is one of the most competitive," explained Wistar's Director, Dr. Giovanni Rovera. "Their willingness to support the completion of the Taxin Center tells the world that it is important. To be offered this grant, we had to undergo careful scrutiny and meet The Kresge Foundation's highest standards. Their confidence is one more important affirmation of Wistar's leadership in medical research. It brings us both prestige and a tremendous responsibility."

Receipt of the grant is contingent upon Wistar's ability to raise the $917,167 balance required to complete funding of the project by January 1, 1999. To date, more than $2,667,000 has come from individuals, private philanthropic foundations and other sources toward an overall cost of $3,584,000.

"Our donors recognize the significance of the endorsement that comes with a Kresge Foundation grant, and I am confident they will respond generously to this challenge," said C. Edwin Davis, Wistar's Director of Development. "During the next few months, we will be appealing to past, current and prospective donors for their help. Commitments will be accepted in the form of one-time gifts or multi-year pledges."

Donors who contribute $3,000, $5,000, $10,000 or $25,000 will receive distinguished recognition as Founding Members of the Albert R. Taxin Brain Tumor Research Center. All donors of $100 or more will be recognized in Wistar's annual report for the year in which the gift is made.

In 1997, The Kresge Foundation received 607 proposals and awarded grants to 180 organizations. "In this cycle of grant making, our Trustees were pleased to support a range of organizations reflecting almost the entire breadth of the nonprofit sector," said Marshall. "This diverse group is responding to the new challenges presented by their communities or sustaining activities that have demonstrated their effectiveness."

The Taxin Center was established in June 1994 in memory of Albert Taxin, the Philadelphia restauranteur who died in 1993 of an incurable and inoperable brain tumor.

The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.
-end-


The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.